Canada & Merck & Co.

Canada: Canada, through Canada — Health Canada, contributes to the supportive regulatory environment in North America.

Merck & Co.: Merck & Co. is a key player in the antibody therapeutics market, benefiting from the projected market growth.

Canada: Canada is a potential market, with melanoma incidence and patient advocacy groups responding positively.

Merck & Co.: Merck is the partner in developing the vaccine and provides Pembrolizumab, which is combined with the vaccine. The trial success offers a new growth avenue as Pembrolizumab faces patent expiration, and its stock rose about 11%.

Canada: Similarly uses combination MMR, highlighting inconsistency in the administration's claims.

Merck & Co.: Manufacturer of the MMR vaccine, stated no scientific benefit to splitting it. Faces potential regulatory and market pressure if separate vaccines are developed, but currently no immediate financial impact.

Canada: Canada is mentioned as a co-host of the World Cup, which the Democratic Republic of the Congo football team cancelled its training camp for due to the Ebola outbreak.

Merck & Co.: Merck & Co. is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.